RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • May 4th, 2021 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Atara Biotherapeutics, Inc.(“Atara”), a company organized under the Laws of Delaware, whose office is situated at 611 Gateway Blvd, Suite 900, South San Francisco, CA 94080, U.S.A.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL, AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Exclusive License Agreement • May 4th, 2021 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS FIRST AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “First Restated Agreement”), entered into on March 22, 2021 (“Execution Date”), is by and between Memorial Sloan Kettering Cancer Center (“MSK”), a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, and Atara Biotherapeutics, Inc. (“Licensee”), a corporation with offices at 611 Gateway Blvd, Suite 900, South San Francisco, CA 94080. MSK and Licensee are sometimes referred to singly as “Party” and collectively as “Parties.”
LEASE AGREEMENTLease Agreement • May 4th, 2021 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT (this “Lease”) is made this 17th day of March, 2021, between ARE-LA REGION NO. 2, LLC, a Delaware limited liability company (“Landlord”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
